Featured Research

from universities, journals, and other organizations

Civil war inside our cells: Scientists show how our bodies fight off 'jumping genes'

Date:
April 25, 2014
Source:
University of Michigan Health System
Summary:
There’s a civil war going on inside every one of the 37 trillion cells in your body. Now, scientists have uncovered how your cells keep this war from causing too much collateral damage. On one side of the battle: your “regular” DNA, which provides the day-to-day instructions for life. On the other side: tiny bits of rogue DNA that hide like spies between genes in your own DNA. From time to time, these rogue bits of DNA spin off a copy of themselves and “jump” to another DNA location – often causing harmful mutations when they land.

There's a civil war going on inside every one of the 37 trillion cells in your body. Now, University of Michigan scientists have uncovered how your cells keep this war from causing too much collateral damage.

On one side of the battle: your "regular" DNA, which provides the day-to-day instructions for life. On the other side: tiny bits of rogue DNA that hide like spies between genes in your own DNA. From time to time, these rogue bits of DNA spin off a copy of themselves and "jump" to another DNA location -- often causing harmful mutations when they land.

How our cells fight off the effects of these rogue DNAs, called LINE-1 retrotransposons, has remained a mystery. But in a new paper published in the open-access journal eLife, scientists from the University of Michigan Medical School and Howard Hughes Medical Institute and colleagues have captured the action like battlefield reporters.

They zeroed in on the defensive activity of an enzyme called APOBEC3A -- and showed that it can cause mutations within the LINE-1 retrotransposons as they jump to new locations. This prevents subsequent invasions into other areas of DNA.

This defensive strike sends out a signal to other defense forces inside the cell, which neutralize the jumping gene and sweep away the destroyed copy.

The findings not only help explain a mystery of the body -- they also may help in the development of cancer drugs. That's because other APOBEC enzymes cause cancer-related mutations -- a kind of "friendly fire" that makes these enzymes a potential target for new drugs.

The new findings about APOBEC3A's ability to squelch LINE-1 activity could mean that blocking APOBEC3 with new cancer drugs might carry consequences.

John Moran, Ph.D., the U-M and HHMI geneticist who led the work with Sandra Richardson, Ph.D., says the new finding gives scientists the first proof of a hypothesized defense strategy.

"It's often hard to see what normally happens during an efficient process that occurs inside our cells," he explains. "But by blocking the process that would normally clean up the evidence of this interaction, we can start to see what is going on."

Dangerous junk

Our cells may each contain as many as 500,000 copies of LINE-1, says Moran, the Gilbert S. Omenn Collegiate Professor of human genetics and professor of internal medicine at U-M and an HHMI research investigator.

LINE-1 is part of the so-called "junk DNA" that makes up half of our genetic material -- but the purpose of "junk DNA" is unclear.

Most LINE-1 copies lay dormant, but a few dozen active copies reside in each cell. LINE-1 retrotransposons can activate and jump, making them dangerous junk.

In fact, LINE-1 alone may cause one in every 250 disease-causing mutations in humans.

So, the "junk" moniker doesn't really fit, says Moran -- though he admits we are probably stuck with this label. He and his team have studied LINE-1 and other jumping genes for years, working with colleagues from the University of Pennsylvania and the Salk Institute, who are co-authors on this paper, and, in previous studies, with colleagues at Duke University.

Fighting fire with fire

In addition to fighting LINE-1 jumps that can cause mutations, APOBEC enzymes also fight off certain viruses. In fact, scientists first discovered these enzymes when observing how human cells fight off infection by HIV, the virus that causes AIDS.

Just like HIV, LINE-1 spreads throughout our DNA by making an RNA copy of its genetic sequence. Then, the RNA is copied back into a new LINE 1 copy that can slide into a new location in our DNA -- a process called retrotransposition.

In this new paper, the researchers show that LINE-1 has one important point of vulnerability. When the new DNA copy peels away from the RNA, an APOBEC3A molecule can attach and change some of the "letters" or base-pairs (rungs on the DNA ladder) in the DNA sequence. Specifically, it changes the "C" bases to "U" bases. The presence of those U bases triggers the cell's cleanup mechanism to come in and dismantle the new copy of the rogue DNA.

In other words, APOBEC3A preempts a potential mutation by LINE-1 jumping, by itself causing a mutation in the new LINE-1 copy that the cell then destroys. But APOBEC3A can pose a mutation danger to the rest of our DNA -- which means our cells must strike a balance between a vigorous defense and the danger of friendly fire.

This kind of intracellular "immunity" may have been raging since the beginnings of life on earth, Moran speculates. LINE-1 contains the code for a molecule called reverse transcriptase -- the kind of molecule that would have been crucial when higher life forms started to evolve and use DNA instead of the less stable RNA to carry genetic information.

Moran and his colleagues will continue to study the importance of the APOBEC family of enzymes in fighting the effects of jumping genes.

They hope to study APOBEC's importance in fighting off mutations early in the development of embryonic life, and in the development of the eggs and sperm that carry our genes to the next generation. Now that they have shown how this defense mechanism works in cultured cells, they hope to study the importance of LINE-1 jumping and the defenses against it in specific diseases.


Story Source:

The above story is based on materials provided by University of Michigan Health System. Note: Materials may be edited for content and length.


Journal Reference:

  1. S. R. Richardson, I. Narvaiza, R. A. Planegger, M. D. Weitzman, J. V. Moran. APOBEC3A deaminates transiently exposed single-strand DNA during LINE-1 retrotransposition. eLife, 2014; DOI: 10.7554/eLife.02008

Cite This Page:

University of Michigan Health System. "Civil war inside our cells: Scientists show how our bodies fight off 'jumping genes'." ScienceDaily. ScienceDaily, 25 April 2014. <www.sciencedaily.com/releases/2014/04/140425091846.htm>.
University of Michigan Health System. (2014, April 25). Civil war inside our cells: Scientists show how our bodies fight off 'jumping genes'. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2014/04/140425091846.htm
University of Michigan Health System. "Civil war inside our cells: Scientists show how our bodies fight off 'jumping genes'." ScienceDaily. www.sciencedaily.com/releases/2014/04/140425091846.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins